Tag: ampligen

October 10, 2018

Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center

Hemispherx Biopharma (NYSE:HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in...
September 18, 2018

Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Hemispherx Biopharma (NYSE:HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen (rintatolimod),...
January 11, 2017

Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that the rintatolimod European early access program (EAP) designed to...
November 10, 2016

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update

Hemispherx Biopharma announced today that it anticipates filing its 2016 third quarter financial results for the quarter ended September 30,...
October 19, 2016

Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone

Hemispherx Biopharma announced today that it has completed its technology transfer of the Ampligen® manufacturing processes to Avrio Biopharmaceuticals.
August 31, 2016

Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering

PHILADELPHIA, Aug. 31, 2016 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”), announced today that it has...
August 23, 2016